Analyzing Entrada Therapeutics (NASDAQ:TRDA) & Bolt Biotherapeutics (NASDAQ:BOLT)

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Entrada Therapeutics and Bolt Biotherapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 1 2 4 0 2.43
Bolt Biotherapeutics 1 1 2 0 2.25

Entrada Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 226.19%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 166.30%. Given Entrada Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Entrada Therapeutics is more favorable than Bolt Biotherapeutics.

Earnings and Valuation

This table compares Entrada Therapeutics and Bolt Biotherapeutics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entrada Therapeutics $25.42 million 7.91 -$143.75 million ($3.84) -1.34
Bolt Biotherapeutics $7.70 million 1.85 -$33.38 million ($14.97) -0.36

Bolt Biotherapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Entrada Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Entrada Therapeutics and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics -4,057.98% -64.00% -50.49%
Bolt Biotherapeutics -611.47% -154.11% -57.59%

Insider and Institutional Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Entrada Therapeutics beats Bolt Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.